The expiration of Novo Nordisk's patent for semaglutide has initiated a significant shift in India's obesity drug market, with generics rapidly entering the scene. Following the patent loss on March 20, semaglutide's market share surged to 33% in March, up from 25% the previous month, according to Pharmarack. This increase came at the expense of Eli Lilly's Mounjaro, which saw its share decline from 71% to 64%. The generics are being offered at prices as low as ₹1,290 (approximately $15.50 USD), providing a stark contrast to the original drug's pricing. The obesity drug segment is projected to expand dramatically, with estimates suggesting it could reach ₹8,000 crore (roughly $960 million USD) by 2030, up from about ₹1,500 crore (approximately $180 million USD) currently. Leading Indian pharmaceutical companies, including Torrent Pharmaceuticals and Sun Pharmaceuticals, have quickly capitalized on this opportunity, with Torrent now holding an 8% market share. The demand for these generics is expected to grow further as companies innovate in drug delivery and patient support, enhancing accessibility and comfort for users.